---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-029872"
form_type: "8-K"
ticker: "JSPR"
cik: "0001788028"
company_name: "Jasper Therapeutics, Inc."
filed_at: "2023-04-14T23:59:59+00:00"
generated_at: "2026-06-17T02:06:30.387821+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Jasper Therapeutics adds CEO vesting acceleration, extends chairperson term

## Summary
- Chairperson William Lis term extended to Mar 15, 2024; annual cash comp reduced to $125K from $250K effective Apr 1, 2023.
- CEO Ronald Martell: if terminated without cause/good reason within 24 months post-Change in Control, receives 18 months base salary plus full equity vesting.
- Change in Control defined by reference to Jasper's Severance Plan; amendments effective April 13, 2023.

## SEC filing metadata
- accession: 0001213900-23-029872
- form_type: 8-K
- ticker: JSPR
- cik: 0001788028
- company_name: Jasper Therapeutics, Inc.
- filed_at: 2023-04-14T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 1.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1788028/000121390023029872/0001213900-23-029872-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1788028/000121390023029872/ea176965-8k_jasperthera.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-029872
- JSON: https://secwatch.observer/filing/0001213900-23-029872.json
- Plain text: https://secwatch.observer/filing/0001213900-23-029872.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.